Journal
CANCERS
Volume 14, Issue 13, Pages -Publisher
MDPI
DOI: 10.3390/cancers14133175
Keywords
male breast cancer; BRCA; clinical management; PARP inhibitors
Categories
Funding
- University of Aberdeen Development Trust
- Breast Cancer UK
- NHS Grampian Breast Cancer Endowment Fund
- Elphinstone Scholarship
Ask authors/readers for more resources
Male breast cancer is a rare disease with limited treatment evidence for BRCA-related cases, highlighting the need for national and global collaborative efforts. Transformative clinical advancements with PARP inhibitors in female breast cancer and prostate cancer provide valuable insights.
Male breast cancer (MBC) is a rare disease that accounts for less than 1% of all breast cancers and male malignancies. Despite recognised clinico-pathological and molecular differences to female breast cancer (FBC), the clinical management of MBC follows established FBC treatment strategies. Loss of function mutations in the DNA damage response genes BRCA1 and BRCA2, have been strongly implicated in the pathogenesis of MBC. While there have been extensive clinical advancements in other BRCA-related malignancies, including FBC, improvements in MBC remain stagnant. Here we present a review that highlights the lack of treatment evidence for BRCA-related MBC and the required national and global collaborative effort to address this unmet need. In doing so, we summarise the transformative clinical advancements with poly(ADP-ribose) polymerase (PARP) inhibitors in other BRCA-related cancers namely, FBC and prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available